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Introduction {#sec1}
============

The current prescription opioid epidemic has prompted a demand for improvements in clinical pain management ([@bib18]). Over the last decade, opioid prescription rates have risen dramatically, with concurrent increases in opioid-related emergency department visits and overdose mortality. Although this is evidently concerning, opioid analgesics remain an essential component of the modern health care systems and the gold standard of therapy for moderate to severe pain. In addition to opioid-induced hypernociception (OIH), analgesic tolerance is a primary driver of diminished pain control and dose escalations in the clinical setting ([@bib16], [@bib5]). Primary afferent sensory neurons are the first-order components of nociceptive sensation and integral to the process of analgesic tolerance development ([@bib17]). We recently demonstrated that chronic morphine exposure in mice results in cellular level tolerance of small diameter primary afferent neurons isolated from L~5~-S~1~ dorsal root ganglia (DRG; [@bib30]). Neurons from tolerant mice demonstrated resistance to morphine-mediated reductions of excitability (i.e., increases in action potential threshold). This raises critical questions about the physiological basis of morphine action and tolerance in small diameter DRG neurons, particularly in regard to modulation of ionic conductances.

Numerous distinct voltage-gated sodium (Na~v~) channels have been described in DRG neurons ([@bib33], [@bib22], [@bib49], [@bib20], [@bib42], [@bib46]). Only two of these (Na~v~1.8 and Na~v~1.9) demonstrate resistance to the puffer fish guanidinium toxin tetrodotoxin (TTX) in the micromolar range. These unusual Na^+^ channels are almost exclusively expressed by small nociceptive primary afferents ([@bib4]), with some nociceptors expressing only tetrodotoxin-resistant (TTX-R) Na^+^ currents ([@bib41]). We and others have demonstrated that chronic (5--7 days) morphine exposure can alter the voltage dependence of activation and steady-state inactivation of TTX-R Na^+^ channels ([@bib14], [@bib47]). Specifically, Ross et al. noted hyperpolarization of the potential of half-maximum (*V*~*1/2*~) activation in mouse DRG neurons. Chen et al. independently reproduced this finding in rat neurons, additionally observing hyperpolarization of the action potential threshold (*V*~*t*~) and acceleration of inactivation kinetics. Both of these studies utilized a chronic morphine exposure paradigm that demonstrated neuronal hyperexcitability associated with OIH. However, there is evidence that even acute morphine challenge *in vitro* can modulate TTX-R Na^+^ channel availability. In an investigation of steady-state inactivation by Smith et al. in mouse enteric neurons a nearly 50% reduction in the number of TTX-R Na^+^ channels available for activation at hyperpolarized potentials with acute morphine challenge was noted (3 μM; [@bib54]). These findings collectively suggest that acute morphine challenge *in vitro* may operate on the same cellular machinery that is modified with chronic morphine exposure, that is, the voltage dependence and/or kinetics of TTX-R Na^+^ channel activation and inactivation in DRG neurons.

There is growing awareness for the role of gastrointestinal microbiota in numerous physiological and pathophysiological processes. Recent investigations have documented the impact of opioids in inducing dysbiosis of gastrointestinal microbiota in both mice and humans ([@bib61]). In this context, *dysbiosis* is defined as a disruption in the composition and/or localization of the gut microflora. We and others have demonstrated that chronic morphine exposure in mice results in such dysbiosis, marked by alterations of microbial composition and compromise of gut epithelial tight junction integrity ([@bib35], [@bib30]). The latter results in gut "leakiness," which allows translocation of luminal bacteria to the gut wall and circulation. Secondary release of bacterial products and pro-inflammatory cytokines correlates with the production of antinociceptive tolerance. Indeed, we noted that concurrent treatment with antibiotics was sufficient to prevent both behavioral antinociceptive tolerance and cellular level tolerance in small diameter DRG neurons. Oral vancomycin alone was sufficient to reproduce the behavioral findings, suggesting that it may also be sufficient to reproduce the cellular level findings; namely, vancomycin may preserve the depolarizing shifts in action potential threshold with acute morphine challenge (3 μM) *in vitro*, which are mitigated in cells from tolerant subjects. The ionic basis of such an effect may also involve TTX-R Na^+^ channels.

Finally, it is as of yet unclear whether the observed impacts of gastrointestinal microbiota on morphine tolerance are a gut-localized or a more general systemic phenomenon. To address this question, we have employed a novel technique that utilizes colon tissue supernatants to grossly assess how mediators in the gut microenvironment affect naive DRG neurons. This innovative approach has arisen as a powerful paradigm for investigating the mechanisms of peripheral nociception in both mice and human patients ([@bib7], [@bib13], [@bib2]). The effects of supernatant exposure can be characterized *in vitro*; then the causal constituents may be later identified and tested in basic or whole-animal systems. To this end, colon tissue supernatants from mice with chronic morphine exposure may be applied to isolated DRG neurons from naive mice to assess the impact of gut-localized mediators (e.g., bacterial products and pro-inflammatory cytokines) on neuronal excitability and morphine tolerance. The importance of the gastrointestinal microbiome in these findings can be additionally assessed using supernatants from mice with concurrent oral vancomycin exposure.

Results {#sec2}
=======

Antinociceptive Morphine Tolerance Prevention by Oral Vancomycin Is Dependent on the Duration of Treatment {#sec2.1}
----------------------------------------------------------------------------------------------------------

We recently demonstrated that oral vancomycin treatment in mice prevents the development of antinociceptive morphine tolerance in the tail immersion assay ([@bib30]). The virtual 0% bioavailability of oral vancomycin suggests a role for gastrointestinal microbiota in this process. Quantification of the total bacterial 16S rRNA gene copies in fecal samples from mice receiving a mixed antibiotic cocktail indicated a temporally dependent reduction of colonic bacterial colonization throughout the 10-day treatment period. We thereby hypothesized that varying the duration of treatment would modulate the efficacy of oral vancomycin in preventing antinociceptive tolerance.

To this end, antinociceptive tolerance development following implantation of a 75-mg morphine pellet was monitored in mice receiving 5, 10, or 15 days of vancomycin (10 mg/kg VAN) treatment by oral gavage ([Figure 1](#fig1){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}). Control subjects received 10 days of saline (SAL) by oral gavage. Latency to tail flick in the tail immersion assay was recorded daily for each treatment cohort. Mice from all cohorts demonstrated a robust antinociceptive response on day 1 after pellet implantation, marked by a sharp increase in latency to tail flick. Mice receiving saline gavage treatments (10 day SAL) developed tolerance to this effect, evidenced by a return of tail flick latency to baseline values by day 3 and a lack of response to acute morphine challenge (10 mg/kg, subcutaneously) on the final testing day. Mice receiving 5 days of vancomycin treatment (5 day VAN, i.e., VAN and morphine pellet \[MP\] initiated simultaneously) demonstrated a significant increase in latency to tail flick on day 2 (p \< 0.001 versus 10 day SAL), but ultimately developed tolerance as well. In contrast, tolerance development was prevented in mice receiving 10 days of vancomycin treatment (10 day VAN), manifested by a significant increase in latency to tail flick on all test days (p \< 0.001 versus 10day SAL) and an additional increase in latency with acute morphine challenge on the final test day. This tolerance prevention was further enhanced in mice receiving 15 days of vancomycin treatment (15 day VAN), demonstrated by a significant increase in tail-flick latencies on all test days (p \< 0.001 versus 10 day VAN).Figure 1Antinociceptive Morphine Tolerance in Mice Is Prevented by Oral Vancomycin in a Manner Dependent on the Duration of Treatment(A) Schematic of the treatment regimen utilized for each cohort in this study.(B) Tail-immersion assay for mice receiving 5, 10, or 15 days of oral vancomycin (VAN, 10 mg/kg). Control subjects received 10 days of oral saline (SAL). Following morphine pellet (MP) implantation, the 10 day SAL and 5 day VAN cohorts demonstrated a progressive reduction in tail-flick latency and lacked a response to acute morphine challenge on day 5 (10 mg/kg, subcutaneously), indicating tolerance development. The 10 day VAN treatment resulted in a significant increase in tail-flick latency throughout the testing period (versus 10 day SAL) and an additional increase with acute morphine challenge on day 5, indicating tolerance prevention. This tolerance prevention was significantly enhanced with 15 day VAN treatment (versus 10 day VAN). 10 day SAL (N = 8), 5 day VAN (N = 10), 10 day VAN (N = 14), 15 day VAN (N = 10); significance indicated versus 10 day SAL (filled symbols, p \< 0.05) and versus 10 day VAN (^†^p \< 0.001, ^‡^p \< 0.0001) by two-way repeated-measures ANOVA with Bonferroni post hoc analysis; data expressed as mean ± SEM (see [Table S1](#mmc1){ref-type="supplementary-material"} for additional values).

Oral Vancomycin Prevents Tolerance to Morphine-Mediated Reductions of Excitability in Small Diameter DRG Neurons {#sec2.2}
----------------------------------------------------------------------------------------------------------------

Our previous investigations have demonstrated the ability of an antibiotic cocktail to prevent cellular level tolerance development in small diameter primary afferent neurons isolated from L~5~-S~1~ DRG ([@bib30]). In current clamp, neurons from non-tolerant mice demonstrated a reduction of excitability with acute morphine challenge (i.e., depolarization of the action potential threshold), whereas neurons from mice with chronic morphine exposure displayed no significant response. This chronic morphine-induced tolerance was prevented in mice receiving concurrent treatment with broad-spectrum antibiotics. We thereby hypothesized that our behavioral observations with vancomycin alone would similarly be reflected by these cellular level tolerance studies.

Responses to acute morphine challenge (3 μM) *in vitro* were assessed in small diameter (\<30 pF) DRG neurons isolated from mice receiving chronic morphine exposure and 10 days of oral vancomycin treatment ([Figures 2](#fig2){ref-type="fig"}A and 2B and [Table S2](#mmc1){ref-type="supplementary-material"}). Whole-cell current-clamp experiments demonstrated a reduction of excitability following acute morphine challenge, evidenced by a significant decrease in the number of action potentials at double rheobase (1.7 ± 0.2 at baseline versus 1.1 ± 0.1 with morphine, p \< 0.01) and depolarization of the action potential threshold (−14.5 ± 1.2 mV at baseline versus −11.3 ± 1.4 mV with morphine, p \< 0.001).Figure 2Characterization of Responses to Acute Morphine Challenge in Small Diameter DRG Neurons(A and B) Oral vancomycin treatment (VAN, 10 mg/kg) for 10 days blocks cellular level morphine tolerance in DRG neurons. Representative raw traces (*left*) and individual observations (*right*) indicate the number of action potentials at double rheobase (A) and action potential threshold (B) at baseline (*black*) and following acute morphine challenge (3 μM, *red*). Morphine perfusion significantly reduced the number of action potentials at double rheobase and depolarized the action potential threshold. (N = 7, n = 18), \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed paired Student\'s t test; data expressed as mean ± SEM.(C) Acute morphine challenge is unable to reduce the excitability of DRG neurons in the presence of naloxone (1 μM). The action potential threshold (*left*) and number of action potentials at double rheobase (*right*) are presented at baseline (*black*) and following acute morphine challenge (3 μM, *red*). No significant shift in either parameter was noted. N = 4, n = 9; ns, not significant by two-tailed paired Student\'s t test; data expressed as mean ± SEM.(D) Morphine-induced depolarizations of action potential threshold persist in the complete absence of internal and external Ca^2+^. The thresholds for each cell are presented at baseline (*black*) and following acute morphine challenge (3 μM, *red*) and indicate a significant depolarization with morphine perfusion. N = 5, n = 7; \*p \< 0.05 by two-tailed paired Student\'s t test (see [Table S2](#mmc1){ref-type="supplementary-material"} for additional values).

Acute Morphine-Induced Reductions of Excitability in Small Diameter DRG Neurons Are Mitigated by the MOR Antagonist Naloxone {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------

To examine whether our observations with acute morphine challenge *in vitro* are mediated by action at μ-opioid receptors (MORs), morphine responses were assessed in small diameter DRG neurons from naive mice in the presence of the MOR antagonist naloxone (1 μM; [Figure 2](#fig2){ref-type="fig"}C and [Table S2](#mmc1){ref-type="supplementary-material"}). Whole-cell current-clamp experiments revealed no significant alteration of excitability following acute morphine challenge (3 μM), manifested by a lack of change in the number of action potentials at double rheobase (1.8 ± 0.3 at baseline versus 1.8 ± 0.3 with morphine) or the action potential threshold (−12.9 ± 1.5 mV at baseline versus −12.2 ± 1.6 mV with morphine).

Acute Morphine-Induced Depolarization of Action Potential Threshold in Small Diameter DRG Neurons Occurs in the Absence of Ca^2+^ {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------

There is a significant body of evidence documenting the modulation of Ca^2+^ currents by opioids in DRG neurons ([@bib25], [@bib52], [@bib38]). To examine whether acute morphine-induced shifts in action potential threshold are wholly mediated by modulation of Ca^2+^ currents, morphine responses were recorded in small diameter DRG neurons from naive mice in the complete absence of internal and external Ca^2+^ ([Figure 2](#fig2){ref-type="fig"}D and [Table S2](#mmc1){ref-type="supplementary-material"}). Whole-cell current-clamp experiments demonstrated a significant depolarization of the action potential threshold following acute morphine challenge (3 μM; −12.3 ± 2.9 mV at baseline versus −8.8 ± 3.2 mV with morphine, p \< 0.05). This suggests the involvement of a Ca^2+^-independent signaling mechanism in mediating morphine-induced shifts of the action potential threshold.

Acute Morphine Challenge in Small Diameter DRG Neurons Reduces the Magnitude of TTX-R Na^+^ Currents by Enhancing Channel Inactivation {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------

Previous investigations in mice suggest a potential role for TTX-R Na^+^ currents in mediating cellular level responses to acute morphine challenge *in vitro*. To assess this, morphine responses were recorded in small diameter DRG neurons from mice receiving chronic exposure to an MP or a placebo pellet (PP) and 10 days of vancomycin (VAN) or saline (SAL) by oral gavage. TTX-R Na^+^ currents were isolated, and whole-cell voltage-clamp experiments were performed utilizing a double-pulse protocol (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Representative raw traces from the conditioning pulse ([Figure 3](#fig3){ref-type="fig"}) and current-voltage (*I*-*V*) relationships ([Figure 4](#fig4){ref-type="fig"}) indicate a significant reduction of peak TTX-R Na^+^ current densities in neurons from PP + SAL and PP + VAN mice in the −10 to +20 mV range (p \< 0.001 and p \< 0.01, respectively). This effect was mitigated in neurons from MP + SAL mice (indicating tolerance development), but preserved in neurons from MP + VAN mice (indicating tolerance prevention; p \< 0.0001) (see [Figure S1](#mmc1){ref-type="supplementary-material"} for non-normalized *I*-*V* curves). In concurrence with previous investigations ([@bib14]), non-normalized current densities ([Figure S2](#mmc1){ref-type="supplementary-material"}) demonstrated a trend toward enhanced magnitude in mice with chronic morphine exposure (MP) compared with placebo (PP). However, this effect was not statistically significant in this study.Figure 3Representative Voltage-Clamp Traces of TTX-R Na^+^ Currents in the Absence and Presence of Acute Morphine ChallengeRaw traces for voltage steps from −10 to +20 mV are presented at baseline (*black*) and following acute morphine challenge (3 μM, *red*). Neurons from PP + SAL and PP + VAN mice demonstrate a significant reduction in the magnitude of inward currents following morphine perfusion. This effect is mitigated in neurons from MP + SAL mice (indicating tolerance development), but preserved in neurons from MP + VAN mice (indicating tolerance prevention). A notable trend toward enhancement of inward current magnitude was noted in cohorts administered morphine pellet (MP) when compared with cohorts given placebo (PP). However, this effect was not statistically significant in this study.Figure 4Acute Morphine Challenge Results in Reduction of TTX-R Na^+^ Current Magnitude That Is Prevented by Chronic Morphine Exposure *In Vivo*, but Preserved with Concurrent Oral Vancomycin TreatmentCurrent-voltage (*I*-*V*) relationships of TTX-R Na^+^ channels in voltage-clamped DRG neurons are shown at baseline (*black*) and following acute morphine challenge (3 μM, *red*). Neurons from PP + SAL and PP + VAN mice demonstrate a significant reduction of current density for steps from −10 to +20 mV. This effect was mitigated in neurons from MP + SAL mice (indicating tolerance development), but preserved in neurons from MP + VAN mice (indicating tolerance prevention). PP + SAL (N = 7, n = 7), PP + VAN (N = 4, n = 6), MP + SAL (N = 7, n = 9), MP + VAN (N = 5, n = 7), \*p \< 0.05, ^\#^p \< 0.01, ^†^p \< 0.001, ^‡^p \< 0.0001 by two-way repeated-measures ANOVA with Bonferroni post hoc analysis; data expressed as mean ± SEM.

To test whether acute morphine challenge (3 μM) modulates the voltage dependence of TTX-R Na^+^ channel activation, the peak current densities utilized for construction of *I*-*V* curves were transformed to relative conductances (*G/G*~*max*~) and fit with a Boltzmann function (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). No significant shifts in the voltage of half-maximum *(V*~*1/2*~*)* activation or slope factor (*k*) were noted in any of the treatment cohorts with acute morphine challenge ([Figure 5](#fig5){ref-type="fig"} and [Table S3](#mmc1){ref-type="supplementary-material"}). Boltzmann fit models within each treatment group were compared by ordinary least squares non-linear regression. No significant difference in fit parameters was detected in any of the treatment cohorts following acute morphine challenge ([Table S3](#mmc1){ref-type="supplementary-material"}). This is reflected by the near-zero output values for the F-ratio test statistic (*F*) and difference in Akaike information criterion (*ΔAIC*).Figure 5Acute Morphine Challenge Does Not Alter the Voltage Dependence of Activation of TTX-R Na^+^ ChannelsRelative conductances (*G/G*~*max*~) of TTX-R Na^+^ channels at baseline (*black*) and following acute morphine challenge (3 μM, *red*). Values transformed from *I*-*V* curves are plotted as a function of the step potential and fit with a Boltzmann function (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). No significant shifts in the voltage of half-maximum (*V*~*1/2*~) activation, slope factor (*k*), or Boltzmann fit parameters are noted in any of the treatment cohorts following acute morphine challenge. PP + SAL (N = 7, n = 7), PP + VAN (N = 4, n = 6), MP + SAL (N = 7, n = 9), MP + VAN (N = 5, n = 7), analyzed by two-way repeated-measures ANOVA with Bonferroni post hoc analysis and ordinary least squares non-linear regression; data expressed as mean ± SEM (see [Table S3](#mmc1){ref-type="supplementary-material"} for additional values).

To examine the effects of acute morphine challenge (3 μM) on steady-state inactivation, the relative peak current density (*I/I*~*max*~) elicited by the test pulse was plotted as a function of the conditioning pulse potential and fit with a Boltzmann function ([Figure 6](#fig6){ref-type="fig"} and [Table S4](#mmc1){ref-type="supplementary-material"}). Acute morphine challenge reduced *I/I*~*max*~ at all potentials tested in neurons from PP + SAL and PP + VAN mice, indicating enhanced inactivation. This effect was mitigated in neurons from MP + SAL mice (indicating tolerance development), but preserved in neurons from MP + VAN mice (indicating tolerance prevention). Notably, the voltage of half-maximum (*V*~*1/2*~) inactivation and slope factor (*k*) did not vary with acute morphine in any of the treatment cohorts. Boltzmann fit models within each treatment group were compared by ordinary least squares non-linear regression. Neurons from PP + SAL and PP + VAN mice demonstrated a significant difference in fit parameters following acute morphine challenge (p \< 0.0001; [Table S4](#mmc1){ref-type="supplementary-material"}). This effect was again mitigated in neurons from MP + SAL mice, but preserved in neurons from MP + VAN mice (p \< 0.0001). These findings are reflected by the diminutive values of *F* and *ΔAIC* in MP + SAL mice compared with all other groups. To assess whether the time-dependent rate of TTX-R Na^+^ channel inactivation is affected by acute morphine challenge (3 μM), inactivation time constants (*τ*~*inactiv*~) were estimated by fitting a monoexponential function to the falling phase of the conditioning pulse current traces at various potentials ([Figure S3](#mmc1){ref-type="supplementary-material"}). Although a general trend toward reduction of *τ*~*inactiv*~ with acute morphine challenge was noted, no significant modulation was detected in any cohort in this study.Figure 6Acute Morphine Challenge Enhances Steady-State Inactivation of TTX-R Na^+^ ChannelsRelative peak current density (*I/I*~*max*~) of TTX-R Na^+^ channels at baseline (*black*) and following acute morphine challenge (3 μM, *red*). Values obtained during the test pulse are plotted as a function of the conditioning pulse potential and fit with a Boltzmann function (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Boltzmann fit comparisons indicate that acute morphine challenge reduced *I/I*~*max*~ (i.e., enhanced inactivation) at all potentials tested in neurons from PP + SAL and PP + VAN mice. This effect was mitigated in neurons from MP + SAL mice (indicating tolerance development), but preserved in neurons from MP + VAN mice (indicating tolerance prevention). No significant shifts in the voltage of half-maximum (*V*~*1/2*~) inactivation and slope factor (*k*) were noted in any of the treatment cohorts with acute morphine challenge. PP + SAL (N = 7, n = 7), PP + VAN (N = 4, n = 6), MP + SAL (N = 7, n = 9), MP + VAN (N = 5, n = 7), analyzed by two-way repeated-measures ANOVA with Bonferroni post hoc analysis and ordinary least squares non-linear regression; data expressed as mean ± SEM (see [Table S4](#mmc1){ref-type="supplementary-material"} for additional values).

Mediators in the Colon of Mice with Chronic Morphine Exposure Induce Tolerance in Naïve Small Diameter DRG Neurons That Is Prevented by Concurrent Oral Vancomycin Treatment {#sec2.6}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To test whether mediators in the colon microenvironment can independently induce tolerance in DRG neurons, colonic supernatants were collected from each treatment cohort and applied to naive DRG neuron cultures (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}; [Figures 7](#fig7){ref-type="fig"}, [8](#fig8){ref-type="fig"}, [9](#fig9){ref-type="fig"}, and [S4](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc1){ref-type="supplementary-material"}). Whole-cell current-clamp experiments were performed to monitor the effect of acute morphine challenge (3 μM) on cell excitability. The number of action potentials at double rheobase is shown for each cohort in [Figures 7](#fig7){ref-type="fig"} and [9](#fig9){ref-type="fig"}. Neurons in supernatants from MP + SAL mice demonstrated significant hyperexcitability at baseline, manifested as an increase in the number of observed action potentials (2.1 ± 0.3 versus PP + SAL 1.2 ± 0.1, p \< 0.05). Excitability in these cells was unaltered by acute morphine challenge (2.1 ± 0.3 at baseline versus 1.9 ± 0.3 with morphine), indicating tolerance development. Neurons in supernatants from MP + VAN mice also demonstrated hyperexcitability at baseline (2.0 ± 0.3 versus PP + VAN 1.1 ± 0.1, p \< 0.05), but responded to acute morphine challenge with a reduction in the number of observed action potentials (2.0 ± 0.3 at baseline versus 1.1 ± 0.1 with morphine, p \< 0.001), indicating tolerance prevention. Neurons in supernatants from PP + SAL and PP + VAN mice largely demonstrated a single action potential at baseline, creating a floor effect that prevented detection of excitability reductions with acute morphine challenge (PP + SAL 1.2 ± 0.1 at baseline versus 1.1 ± 0.1 with morphine; PP + VAN 1.1 ± 0.1 at baseline versus 1.1 ± 0.1 with morphine).Figure 7Representative Current-Clamp Traces for the Number of Action Potentials at Double Rheobase in Colonic Supernatant ExperimentsCurrent-clamp traces at double rheobase are presented at baseline (*black*) and following acute morphine challenge (3 μM, *red*) for naive DRG neurons exposed to colonic supernatants from each treatment cohort. Neurons in supernatants from PP + SAL and PP + VAN mice demonstrated low excitability at baseline, most often characterized by a single action potential at double rheobase. Owing to a floor effect, no reduction could be detected with morphine perfusion. Neurons in supernatants from MP + SAL mice demonstrated enhanced excitability at baseline, characterized by a greater number of action potentials at double rheobase. No reduction was detected with acute morphine challenge, indicating tolerance development. Neurons in supernatants from MP + VAN mice were also hyperexcitable at baseline, but demonstrated a reduction in the number of action potentials at double rheobase with acute morphine challenge, indicating tolerance prevention (see [Figure 9](#fig9){ref-type="fig"} for individual observations).Figure 8Representative Current-Clamp Traces for Action Potential Threshold in Colonic Supernatant ExperimentsAction potential threshold (*V*~*t*~) is presented at baseline (*black*) and following acute morphine challenge (3 μM, *red*) for naive DRG neurons exposed to colonic supernatants from each treatment cohort. Neurons in supernatants from PP + SAL and PP + VAN mice demonstrated low excitability at baseline, characterized by depolarization of *V*~*t*~. Morphine perfusion significantly depolarized *V*~*t*~ further, indicating a lack of tolerance development. Neurons in supernatants from MP + SAL mice demonstrated enhanced excitability at baseline, characterized by hyperpolarization of *V*~*t*~. No depolarization was noted with acute morphine challenge, indicating tolerance development. Neurons in supernatants from MP + VAN mice were also hyperexcitable at baseline, but demonstrated depolarization of *V*~*t*~ with acute morphine challenge, indicating tolerance prevention (see [Figure 9](#fig9){ref-type="fig"} for individual observations).Figure 9Mediators in the Gut Wall of Mice with Chronic Morphine Exposure Induce Tolerance in Naive DRG Neurons That Is Prevented by Oral Vancomycin TreatmentIndividual observations of naive DRG neurons exposed to colonic supernatants from each treatment cohort. Action potentials at double rheobase and action potential threshold (*V*~*t*~) are presented at baseline (*black*) and following acute morphine challenge (3 μM, *red*). Neurons in supernatants from PP + SAL and PP + VAN mice demonstrated low excitability at baseline, characterized by fewer action potentials at double rheobase and depolarization of the action potential threshold (*V*~*t*~). A significant depolarization of *V*~*t*~ was noted with morphine perfusion; however, no alteration in the number of action potentials at double rheobase could be detected owing to a floor effect. Neurons in supernatants from MP + SAL mice demonstrated enhanced excitability at baseline, characterized by more action potentials at double rheobase and hyperpolarization of *V*~*t*~. No shift in either parameter was noted with acute morphine challenge, indicating tolerance development. Neurons in supernatants from MP + VAN mice also demonstrated enhanced excitability at baseline, but responded to acute morphine challenge with reductions in the number of action potentials at double rheobase and depolarizations of *V*~*t*~. PP + SAL (N = 8, n = 9), PP + VAN (N = 6, n = 8), MP + SAL (N = 5, n = 9), MP + VAN (N = 7, n = 8); ns, not significant; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001 by two-way repeated-measures ANOVA with Bonferroni post hoc analysis; data expressed as mean ± SEM (see [Table S5](#mmc1){ref-type="supplementary-material"} for additional values).

The action potential threshold (*V*~*t*~) is shown for each cohort in [Figures 8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}. For neurons in supernatants from MP + SAL mice, hyperexcitability at baseline manifested as hyperpolarization of V~t~ (−20.1 ± 1.3 mV versus PP + SAL -10.8 ± 2.4 mV, p \< 0.05). Again, excitability in these cells was unaltered by acute morphine challenge (−20.1 ± 1.3 mV at baseline versus −19.7 ± 1.3 mV with morphine), indicating tolerance development. Neurons in supernatants from MP + VAN mice were also hyperexcitable at baseline (−21.2 ± 2.1 mV versus PP + VAN -9.2 ± 1.6 mV, p \< 0.01) but responded to acute morphine challenge with depolarizations of *V*~*t*~ (−21.2 ± 2.1 mV at baseline versus −17.4 ± 2.3 mV with morphine), indicating tolerance prevention. Reductions of excitability with acute morphine challenge were revealed in neurons with supernatants from PP + SAL and PP + VAN mice, manifested by depolarizations of *V*~*t*~ (PP + SAL −10.8 ± 2.4 mV at baseline versus −6.9 ± 2.9 mV with morphine, p \< 0.001; PP + VAN -9.2 ± 1.6 mV at baseline versus −4.5 ± 2.6 mV with morphine, p \< 0.0001).

Discussion {#sec3}
==========

The purpose of this study was to investigate the role of TTX-R Na^+^ channels and gut-derived mediators in morphine action and tolerance in small diameter DRG neurons. The salient findings are that (1) oral vancomycin prevents antinociceptive morphine tolerance in a manner dependent on the duration of treatment, (2) oral vancomycin prevents cellular level morphine tolerance in small diameter DRG neurons, (3) acute morphine challenge in small diameter DRG neurons results in inactivation of TTX-R Na^+^ channels, (4) acute morphine-induced inhibition of TTX-R Na^+^ channels is mitigated in cells from tolerant mice, (5) mediators in the gut microenvironment of mice with chronic morphine exposure can induce tolerance and hyperexcitability in naive small diameter DRG neurons, and (6) induction of tolerance (but not hyperexcitability) by gut mediators is mitigated by concurrent treatment with oral vancomycin.

Owing to the clinical and social ramifications of physical dependence and addiction, the mechanisms underlying opioid tolerance development have been studied for decades. Recent evidence suggests that morphine exposure in mice results in dysbiosis of resident gastrointestinal microflora, marked by alterations of microbial composition and compromise of gut epithelial tight junction integrity ([@bib35]). The latter, occurring through mechanisms that involve toll-like receptors (TLRs) 2 and 4, results in gut epithelial "leakiness," which allows translocation of luminal bacteria to the gut wall and circulation. The subsequent release of bacterial products and pro-inflammatory cytokines may modulate the development of morphine tolerance in nociceptive primary afferent neurons. There is some evidence that morphine can non-stereoselectively bind and activate TLR4 receptors in microglia ([@bib58], [@bib27]), whereas the role of this binding in tolerance and OIH remains unresolved ([@bib17]), and both have been noted to develop in TLR4 knockout mice ([@bib21], [@bib34]). In addition, we previously demonstrated that antinociceptive tolerance following chronic morphine exposure in mice could be prevented by concurrent treatment with oral vancomycin, inherently suggesting mechanisms beyond direct TLR4 binding ([@bib30]). In the present study, this tolerance prevention was noted to occur in a manner dependent on the duration of treatment and was recapitulated at the cellular level in isolated DRG neurons. The virtual 0% bioavailability of oral vancomycin suggests a role for gastrointestinal microbiota in this process.

The DRG contain the neuronal soma of both somatic and visceral nociceptive primary afferents, serving as a "relay station" to the central nervous system (CNS). It has been suggested that opioid receptors on these neurons account for 50%--100% of the antinociceptive effect of systemic opioids ([@bib55]). Seminal investigations of opioid action in CNS neurons noted hyperpolarization of resting membrane potential, decrease of action potential duration, and decrease in neurotransmitter release following opioid exposure in myriad cell populations ([@bib53], [@bib39], [@bib62]). Although significant heterogeneity was noted among cell populations ([@bib19]), these observations were primarily attributed to increases in K^+^ efflux and decreases in Ca^2+^ influx. DRG neurons have not demonstrated the hyperpolarization of resting membrane potential and modulation of K^+^ conductance that many central neurons display ([@bib3]). Therefore early investigations in these cells primarily focused on the modulation of Ca^2+^ currents ([@bib25], [@bib52], [@bib38]). The vast majority of such studies isolated Ca^2+^ currents, in part, by replacement of external Na^+^ with non-permeable tetraethylammonium (TEA). This approach may have undermined an important role held by Na^+^ channels in mediating opioid responses in DRG neurons ([@bib23], [@bib24], [@bib14], [@bib47]). Indeed, some early CNS investigations observed inhibition of Na^+^ currents ([@bib40], [@bib1]) and the present study indicated that morphine-induced depolarization of action potential threshold in DRG neurons occurs even in the complete absence of Ca^2+^. The action potential threshold is defined as the value of the membrane potential at which the magnitudes of inward and outward currents contributing to depolarization are exactly equal. Once a triggering event depolarizes the membrane in excess of this value, the positive feedback loop of voltage-gated inward current activation closes and the action potential is observed. The major drivers of this phenomenon have been classically identified as voltage-gated Na^+^ and K^+^ channels. Given that previous investigations in DRG neurons have not noted modulation of K^+^ conductance with opioid exposure ([@bib3]), there is great precedent for studying Na^+^ channels.

Our voltage-clamp investigations of isolated TTX-R Na^+^ currents indicated a significant reduction of current magnitude following acute morphine challenge. Reflecting previous behavioral observations, chronic morphine exposure resulted in tolerance to this effect, which was prevented by concurrent treatment with oral vancomycin. No modulation of the voltage dependence of activation was noted in these records, suggesting that the TTX-R Na^+^ channel open probability (P~open~) curve is unaffected by acute morphine. In contrast, steady-state inactivation studies indicated an enhancement of TTX-R Na^+^ channel inactivation with acute morphine. Chronic morphine exposure again resulted in tolerance to this effect, which was prevented by concurrent treatment with oral vancomycin. Notably, the voltage of half-maximum (*V*~*1/2*~) inactivation, slope factor (*k*), and inactivation time constant (*τ*~*inactiv*~) did not vary with acute morphine in any of the treatment cohorts. This implies that morphine induces complete inactivation in a subset of TTX-R Na^+^ channels (effectively eliminating them from the population available for activation), while leaving the inactivation kinetics of the remaining channels unaltered. It is as of yet unclear whether this inactivation effect is saturable by elevating the challenge dose of morphine or if a subpopulation of TTX-R Na^+^ channels will demonstrate resistance to this effect at all doses.

The mechanism by which acute morphine challenge enhances TTX-R Na^+^ channel inactivation remains elusive. (A model of our working hypothesis is presented in [Figure 10](#fig10){ref-type="fig"}.) MORs are classical G~i/o~-coupled receptors, activation of which stimulates the exchange of GDP for GTP on the G~α~ subunit. The subsequent dissociation of G~α~ and G~βγ~ subunits promotes modulation of ion channel currents and activation of various kinase cascades. The G~α~ subunit interacts with adenylyl cyclase to inhibit the cyclic AMP (cAMP)/protein kinase A (PKA) pathway. The G~βγ~ subunit (1) activates GIRK channels ([@bib56], [@bib57], [@bib50]), (2) inhibits voltage-gated Ca^2+^ channels ([@bib51], [@bib36]), (3) induces recruitment of GRK2/3, (4) activates the mitogen-activated protein kinase (MAPK) cascade (Ras, Raf, MEK, ERK1/2, JNK, p38) in a PI3K-/c-Src-dependent manner ([@bib43], [@bib44], [@bib59]), (5) activates the phospholipase C/protein kinase C pathway, and (6) stimulates Ca2+/calmodulin-dependent protein kinase II ([@bib45]). Inactivation of Na^+^ channels involves protein conformational changes (e.g., of the fast inactivation gate at the S3-S4 intracellular loop; [@bib12]) that result in occlusion of the conduction pore. Others have noted a direct block of sodium channels with the peripherally restricted opioid loperamide ([@bib60]), whereas our studies with naloxone alternatively suggest an MOR-dependent mechanism for morphine in DRG neurons. The observation of tolerance development with chronic morphine exposure supports this, as this process would not likely impede direct inhibition. Inactivation is therefore plausibly propagated by direct G~βγ~ inhibition or modification of intracellular kinase activity that results in a phosphorylation/dephosphorylation event. G~βγ~ is of particular interest, given its known role in modulating the conductance of various ion channels, including Na~v~1.1 and 1.2 ([@bib32]).Figure 10General Schematic of the Working HypothesisMorphine acting acutely on small diameter DRG neurons results in inhibition of TTX-R Na^+^ channels. This action is MOR dependent, likely occurring via direct G~βγ~ inhibition or a downstream phosphorylation/dephosphorylation event. Chronic morphine exposure compromises gut epithelial tight junction integrity, allowing translocation of luminal bacteria and the subsequent release of bacterial products and pro-inflammatory cytokines. These act on small diameter DRG neurons, producing tolerance to the inhibitory action of acute morphine on TTX-R Na^+^ channels. Elimination of Gram-positive gut microbiota by oral vancomycin prevents this tolerance, but does not prevent the upregulation of TTX-R Na^+^ and TRPV1 channels induced by chronic morphine.

The trend toward enhancement of TTX-R Na^+^ currents with chronic morphine exposure in this study has been observed to be significant by others ([@bib14]). Prior investigations have additionally demonstrated a trend toward enhancement of TTX-R Na^+^ channel mRNA expression in whole DRG isolates from these mice ([@bib47]). Although this effect was not significant, the authors rightly noted that the expression might be selectively enhanced in cellular subpopulations (e.g., nociceptors) and that single-cell PCR experiments should be conducted. Furthermore, it is possible that TTX-R Na^+^ channel expression is upregulated without notable changes in mRNA concentration. Indeed, Chen and colleagues demonstrated that TRPV1 surface expression is increased in these neurons without an associated increase in TRPV1 mRNA expression ([@bib15]), suggesting modulation of other cellular mechanisms (e.g., translation, splicing, or trafficking). A comprehensive investigation of this topic with regard to TTX-R Na^+^ currents is undoubtedly necessary.

G~βγ~-induced GRK2/3 recruitment to the MOR results in phosphorylation of the agonist-bound receptor, producing a conformational change in the MOR that increases its affinity for β-arrestin2 (β-Ar2). Binding of β-Ar2 (1) creates steric hindrance that prevents coupling of the MOR to G proteins, (2) promotes receptor internalization by targeting the MOR to clathrin-coated pits, and (3) serves as a scaffolding protein for the activation of various intracellular kinase cascades (e.g., MAPK). Importantly, a prerequisite for β-Ar2 activation of the MAPK cascade is receptor internalization ([@bib31]). Morphine is a poor stimulator of internalization compared with the other opioids, making MAPK activation by this pathway rather ineffective ([@bib59]). For this reason, it is unlikely that inhibition of TTX-R Na^+^ channels by acute morphine challenge occurs via this pathway. However, it should be noted that chronic morphine exposure has been demonstrated to result in adaptive mechanisms that promote the activation of MAPK by β-Ar2 ([@bib6]). MAPK can phosphorylate multiple cytoplasmic and nuclear targets (e.g., CREB) to modulate transcriptional events. As discussed, chronic morphine exposure results in hyperexcitability of DRG neurons associated with enhancement of TTX-R Na^+^ and TRPV1 currents ([@bib15], [@bib47], [@bib54]). It is therefore quite possible that this β-Ar2/MAPK pathway is involved in the cellular adaptive processes that take place with chronic morphine exposure to modulate excitability and tolerance. Supporting this, Chen and colleagues demonstrated that chronic morphine exposure has been linked to an upregulation of TRPV1 in DRG neurons, which is associated with increased phosphorylation of MAPKs (p38, ERK, and JNK; [@bib15]). In this study, inhibition of the MAPK pathway prevented tolerance and hypernociception induced by chronic morphine exposure. It is therefore possible that MAPK is also involved in the modulation of TTX-R Na^+^ channel surface expression and tolerance. Indeed, p38 has been observed to directly phosphorylate Na~v~1.8 channels to increase current density ([@bib26]). Adding to the complexity of this issue, MOR β-Ar2 recruitment per se can modulate channel activity by diverting β-Ar2 away from other molecular targets. This effect has been noted to enhance the sensitivity of TRPV1 channels ([@bib48]). Whether this mechanism could also affect TTX-R Na^+^ currents (directly or indirectly) remains to be determined.

Our investigations with colon tissue supernatants suggest that tolerance and hyperexcitability associated with chronic morphine exposure develop independently and as indirect actions of morphine, presumably downstream of peripheral MOR activation ([@bib17]). The efficacy of oral vancomycin in preventing tolerance development indicates the involvement of Gram-positive microbiota, including translocation and the secondary release of bacterial products and pro-inflammatory cytokines. In this regard, inflammation has been shown to result in significant plasticity of opioid signaling, including receptor expression, G-protein signaling, and receptor trafficking ([@bib64]). Vancomycin did not alter the development of hyperexcitability, indicating a mechanism independent of Gram-positive microbiota. This does not, however, rule out the possibility for involvement of Gram-negative gut microbes or inflammatory mechanisms independent of bacterial translocation. Certainly, direct opioid action on immune cells is well documented, as is the role of TRPV1 in both opioid- and inflammation-induced hypernociception ([@bib10], [@bib11], [@bib28], [@bib15], [@bib47], [@bib54]).

Further characterization of the mechanisms underlying opioid action and tolerance in DRG neurons is undoubtedly necessary. Although visceral sensory afferents account for less than 10% of all DRG neurons ([@bib9]), our investigations did not discriminate for those with gut innervation, implying relevance to somatic sensory afferents as well. Communication with somatic afferents may result from systemically circulating mediators or local activation of satellite glia by visceral afferents. Furthermore, the extent to which morphine-induced inhibition of Na~v~1.8 and 1.9 specifically mediates depolarization of action potential threshold in DRG neurons remains unclear. It is quite possible that inhibition is subtype selective, or even that TTX-sensitive Na^+^ channels are involved. Elucidating such details could greatly affect clinical pain management and improve patient outcomes.
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